Share

January 21, 2014; 82 (3) ArticleOpen Access

Herpes zoster as a risk factor for stroke and TIA

A retrospective cohort study in the UK

Judith Breuer, Maud Pacou, Aline Gauthier, Martin M. Brown
First published January 2, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000038
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
12650

Share

This article has corrections. Please see:

Article Information

vol. 82 no. 3 206-212
DOI: 
https://doi.org/10.1212/WNL.0000000000000038
PubMed: 
24384645
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 6, 2013
  • Accepted in final form October 8, 2013
  • First Published January 2, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Judith Breuer, MD,
    2. Maud Pacou, BSc,
    3. Aline Gauthier, BSc and
    4. Martin M. Brown, MD
  1. Judith Breuer, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. application of targeted enrichment technology to wholeviral genome sequencingNovel method which allows recovery of sufficient viralnucleic acid for whole genome sequencing from clinical samples

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Medical Research Council UK G0700814 Reverse genetics tomap determinants of VZV Oka strain attenuation andvirulence. (PI) March 2008-Feb 2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Maud Pacou, BSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Amaris (consultancy company), position: Statistical Analyst, since 2009

    Consultancies:

    1. (1) Part of the Amaris project team who acted as a consultancy company for the UCL

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Perceived remuneration from Amaris as an employee of this company

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Acted as a consultant to advise on the implementation and interpretation of studies related to epidemiology and statistics in my function of statistical analyst at Amaris

  3. Aline Gauthier, BSc and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Amaris,consultancy company, position:Director, 4 years

    Consultancies:

    1. Part of the Amaris project team, who acted as a consultant for the University College of London (UCL)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Perceived remuneration from Amaris as an employee of this company

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. As serving on the board of directors of Amaris UK

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Acted as a consultant/expert to advise on the implementation and interpretation of studies related to epidemiology, health economics and statistics in my function of director of Amaris

  4. Martin M. Brown, MD
    5. Scientific Advisory Boards:

    1. (1) I received compensation from Bayer Healthcare for the work and travel required as a member of a Data Safety Monitoring Board(2) I received compensation from St Jude Medical for work and travel required as Chairman of a trial Clinical Events Committee(3) I received compensation from Baxter Innovations for for the work and travel required as a member of a for the work and travel required as a member of a Clinical Advisory Board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) National Institute for Health Research, PB-PG-0609-19216, funding for the Second European Carotid Surgery Trial (ECST-2), 2012-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) UCL receives funding for research on carotid stenosis from CORDA(2) MMB's Chair in Stroke Medicine at UCL is supported by the Reta Lila Weston Trust for Medical Research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Infection and Immunity (J.B.), and Institute of Neurology (M.M.B.), University College London; and Amaris (M.P., A.G.).
  1. Correspondence to Dr. Breuer: j.breuer{at}ucl.ac.uk
View Full Text

Article usage

Article usage: January 2014 to January 2020

AbstractFullPdfSource
Jan 201487222787880Highwire
Feb 20141439238551Highwire
Mar 2014825161291Highwire
Apr 2014745133195Highwire
May 201453596160Highwire
Jun 201442285130Highwire
Jul 201431979105Highwire
Aug 20142473583Highwire
Sep 20142253294Highwire
Oct 20142372775Highwire
Nov 20141803658Highwire
Dec 20142473352Highwire
Jan 20152391855Highwire
Jan 201504512pmc
Feb 20152161846Highwire
Feb 201506420pmc
Mar 20152873458Highwire
Mar 2015010418pmc
Apr 20152121456Highwire
Apr 201508136pmc
May 20151691137Highwire
May 2015010476pmc
Jun 20151483222Highwire
Jun 201506916pmc
Jul 20151502123Highwire
Jul 20150747pmc
Aug 20151771530Highwire
Aug 201507916pmc
Sep 20151773426Highwire
Sep 201506522pmc
Oct 20151551733Highwire
Oct 201507811pmc
Nov 2015133947Highwire
Nov 201506612pmc
Dec 20151732147Highwire
Dec 201507121pmc
Jan 20161401644Highwire
Jan 201607211pmc
Feb 20161282139Highwire
Feb 201608015pmc
Mar 20161261836Highwire
Mar 201607416pmc
Apr 201683824Highwire
Apr 20160679pmc
May 2016951115Highwire
May 20160546pmc
Jun 2016119731Highwire
Jun 201607123pmc
Jul 20161011446Highwire
Jul 201606513pmc
Aug 2016129817Highwire
Aug 201608315pmc
Sep 20161121327Highwire
Sep 20160949pmc
Oct 20161101619Highwire
Oct 201609316pmc
Nov 20161201235Highwire
Nov 2016012416pmc
Dec 20167398Highwire
Dec 2016011112pmc
Jan 20171161111Highwire
Jan 2017012411pmc
Feb 20178197Highwire
Feb 201701169pmc
Mar 2017821013Highwire
Mar 2017013815pmc
Apr 201790614Highwire
Apr 2017792100pmc
May 2017901121Highwire
May 201713119148pmc
Jun 201788911Highwire
Jun 20171194105pmc
Jul 20171071619Highwire
Jul 201713158185pmc
Aug 2017932312Highwire
Aug 20172495105pmc
Sep 201771139Highwire
Sep 20178108160pmc
Oct 2017871018Highwire
Oct 201717108128pmc
Nov 201768818Highwire
Nov 2017146986pmc
Dec 201733355Highwire
Jan 2018585616Highwire
Feb 2018554311Highwire
Mar 2018657319Highwire
Apr 2018734713Highwire
Apr 201877886pmc
May 2018754420Highwire
Jun 2018829223Highwire
Jun 201866982pmc
Jul 2018676415Highwire
Aug 2018658815Highwire
Aug 2018136876pmc
Sep 201841526Highwire
Oct 201852729Highwire
Nov 20185914326Highwire
Dec 2018601237Highwire
Jan 2019371327Highwire
Feb 2019371359Highwire
Mar 201925977Highwire
Apr 2019237310Highwire
May 2019369810Highwire
Jun 2019216210Highwire
Jul 201926617Highwire
Aug 201923776Highwire
Sep 201923475Highwire
Oct 201930904Highwire
Nov 201930858Highwire
Dec 201939714Highwire
Jan 202064996Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

More Online

CME Course

Related Articles

Topics Discussed

Alert Me